The mitochondria-targeted antioxidant SkQ1, which alleviated AD pathology through MEK1/2-ERK1/2 pathway suppression in the OXYS rat hippocampus, can be regarded as a promising therapeutic agent against human AD. The gene discussed is MAPK3; the disease is Alzheimer disease.